Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids
Authors:
- 1 March 2017
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (3) , 657-659
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Ipilimumab-associated HepatitisAmerican Journal of Surgical Pathology, 2015
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.Journal of Clinical Oncology, 2015
- Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.Journal of Clinical Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Ipilimumab associated hepatitis: imaging and clinicopathologic findingsInvestigational New Drugs, 2013
- Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver InjuryDigestion, 2011
- Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune HepatitisGastroenterology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitisJournal of Gastroenterology and Hepatology, 1998